Pharming Group rises on UK marketing authorization for drug Joenja

Pharming

26/09/2024 08:25

** Shares in Pharming Group  PHAR.AS  rise 5.2% after the
Dutch biopharmaceutical firm received a marketing authorization
for its drug Joenja (leniolisib) in the UK
    ** It says the drug is currently under evaluation by the
National Institute for Health and Care Excellence (NICE) for NHS
reimbursement
    ** Leniolisib is the first treatment approved in Britain for
APDS, a rare and progressive primary immunodeficiency
    ** Including Thursday's rise, the stock is down 29.4% YTD​

 (Reporting by Dimitri  Rhodes)
 ((Dimitri.Rhodes@thomsonreuters.com;))